ACLARION INC SEC Filings

ACONW NASDAQ

Welcome to our dedicated page for ACLARION SEC filings (Ticker: ACONW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Looking for a fast way to decode how Aclarion funds its Nociscan MR spectroscopy platform or when executives exercise their ACONW warrants? Most investors start by asking where to find Aclarion insider trading Form 4 transactions or how to read an Aclarion annual report 10-K simplified. This page brings every SEC disclosure into one place and answers those questions up front.

Our AI engine turns dense documents into concise insights: understanding Aclarion SEC documents with AI means you can skim a summary instead of 200 pages. New filings flow in directly from EDGAR, so Aclarion Form 4 insider transactions real-time and each Aclarion 8-K material events explained alert appear minutes after submission.

Wondering what to open first?

10-K & 10-Q – The Aclarion quarterly earnings report 10-Q filing details cash burn, clinical-trial spend, and SaaS revenue growth, while our Aclarion earnings report filing analysis highlights key metrics.
Form 4 – Track Aclarion executive stock transactions Form 4 to gauge insider confidence before pivotal trial results.
DEF 14A – The Aclarion proxy statement executive compensation section explains how leadership is incentivized to hit commercialization milestones.

Every filing is paired with plain-language commentary, AI-powered red-flag detection, and keyword search so Aclarion SEC filings explained simply becomes reality. Whether you monitor warrant dilution scenarios or need an at-a-glance view of clinical data disclosures, Stock Titan delivers the information you need, when you need it.

06/20/2025 05:07 PM

Filing

[8-K] Aclarion, Inc. Warrant Reports Material Event

Rhea-AI Summary

Aclarion, Inc. (Nasdaq: ACON) filed an 8-K (Item 5.02) disclosing that Chief Financial Officer John Lorbiecki notified the company on 16 June 2025 of his intention to retire.

The board has initiated an external search and expects to name a new CFO before the end of Q3 2025. Lorbiecki, who has served since October 2021 and guided the April 2022 IPO, will remain in his post for “the next several months” to manage an orderly transition and to sign the upcoming Form 10-Q, which the company plans to file on or before the 14 August 2025 deadline.

The filing states that Lorbiecki’s decision is purely personal (retirement) and "did not result from any disagreement" regarding internal controls, financial statements, audit matters, or related procedures, limiting potential governance red flags.

No financial metrics, business updates, or other material events were reported in this filing.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

FAQ

What is the current stock price of ACLARION (ACONW)?

The current stock price of ACLARION (ACONW) is $0.0319 as of July 1, 2025.

What does Aclarion Inc specialize in?

Aclarion Inc is a healthcare technology company that uses advanced MR spectroscopy, biomarkers, and augmented intelligence algorithms to enhance clinical treatment strategies, particularly for chronic low back pain.

What is the Nociscan platform?

Nociscan is Aclarion's cloud-based SaaS product that noninvasively analyzes MR spectroscopy data to distinguish between painful and nonpainful discs, aiding physicians in accurate diagnosis and treatment planning.

How does Aclarion generate revenue?

The company generates revenue primarily through contracts for delivering detailed Nociscan reports to medical professionals, with revenues concentrated in the United States.

What technological innovations does Aclarion leverage?

Aclarion utilizes innovative MR spectroscopy techniques combined with proprietary signal processing and augmented intelligence algorithms to objectively quantify chemical biomarkers associated with disc pain.

Who are the target customers for Aclarion's products?

Its primary customers are healthcare providers and medical institutions seeking noninvasive diagnostic tools to better assess chronic low back pain and optimize treatment strategies.

How does Nociscan improve diagnostic accuracy?

Nociscan analyzes MRS data to identify specific biomarkers of disc pain, providing objective evidence that supports more precise clinical decision making compared to traditional invasive methods.

What role do clinical partnerships play for Aclarion?

Clinical partnerships and collaborations with key opinion leaders and major healthcare institutions are central to validating Nociscan's effectiveness, facilitating broader adoption, and supporting payer coverage initiatives.

How does Aclarion's approach differ from traditional diagnostic methods?

Unlike conventional invasive procedures used to pinpoint discogenic pain, Aclarion's noninvasive approach leverages MR spectroscopy and advanced analytics to deliver objective, reliable data that enhances clinical treatment decisions.